Angel Biotechnology consolidating business after asset boosting year
News | 01 June 2012
Angel Biotechnology (LON:ANH) said it will concentrate on consolidating the business after an 'intense' asset boosting period of change. Angel, which manufactures products for drug development firms, increased its total assets to
Click on the link to read the full article at Proactive Investors UK
(This link will open in a new window)
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
